Mutant p53 in cancer: New functions and therapeutic opportunities

Cancer Cell

Volumn 25, Issue 3, 2014, Pages 304-317

  Muller, Patricia A J ^a   Vousden, Karen H ^b  

^a MRC TOXICOLOGY UNIT   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; CYCLIN G2; DICER; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE 6; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR FACTOR Y; PROTEIN P53; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UBIQUITIN PROTEIN LIGASE E3; MUTANT PROTEIN;

ALTERNATIVE ENERGY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL DEDIFFERENTIATION; CELL SURVIVAL; CHAPERONE-MEDIATED AUTOPHAGY; CHEMOSENSITIVITY; CHOLESTEROL SYNTHESIS; CLINICAL PATHWAY; COLORECTAL TUMOR; DEACETYLATION; DISEASE COURSE; DNA BINDING; ENZYME INHIBITION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; GENOMIC INSTABILITY; HETEROZYGOSITY; HUMAN; HYPOXIA; IMMUNOCOMPETENT CELL; MACROAUTOPHAGY; MALIGNANT NEOPLASTIC DISEASE; MESENCHYMAL STEM CELL; METASTASIS; MISSENSE MUTATION; NONHUMAN; NULL CELL; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLURIPOTENT STEM CELL; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SENESCENCE; SOMATIC CELL; STEM CELL; STROMA; TISSUE SPECIFICITY; TREATMENT RESPONSE; TUMOR GROWTH; ULTRAVIOLET RADIATION; WILD TYPE; XENOGRAFT; CANCER CELL; CANCER INCIDENCE; CELL MIGRATION; CELL PROLIFERATION;

ANIMALS; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MUTATION; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896098750     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.01.021     Document Type: Review

References (172)

1. Acin S., Li Z., Mejia O., Roop D.R., El-Naggar A.K., Caulin C. Gain-of-function mutant p53 but not p53 deletion promotes head and neckcancer progression in response to oncogenic K-ras. J.Pathol. 2011, 225:479-489.
2. Addadi Y., Moskovits N., Granot D., Lozano G., Carmi Y., Apte R.N., Neeman M., Oren M. p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res. 2010, 70:9650-9658.
3. Adorno M., Cordenonsi M., Montagner M., Dupont S., Wong C., Hann B., Solari A., Bobisse S., Rondina M.B., Guzzardo V., et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009, 137:87-98.
4. Agapova L.S., Ilyinskaya G.V., Turovets N.A., Ivanov A.V., Chumakov P.M., Kopnin B.P. Chromosome changes caused by alterations of p53 expression. Mutat. Res. 1996, 354:129-138.
5. Ali A., Wang Z., Fu J., Ji L., Liu J., Li L., Wang H., Chen J., Caulin C., Myers J.N., et al. Differential regulation of the REGgamma-proteasome pathway by p53/TGF-beta signalling and mutant p53 in cancer cells. Nature communications 2013, 4:2667.
6. Atema A., Chène P. The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers. Cancer Lett. 2002, 185:103-109.
7. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
8. Blandino G., Levine A.J., Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999, 18:477-485.
9. Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., Fersht A.R. Targeted rescue of a destabilized mutant of p53 by an insilico screened drug. Proc. Natl. Acad. Sci. USA 2008, 105:10360-10365.
10. Bossi G., Lapi E., Strano S., Rinaldo C., Blandino G., Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006, 25:304-309.
11. Bossi G., Marampon F., Maor-Aloni R., Zani B., Rotter V., Oren M., Strano S., Blandino G., Sacchi A. Conditional RNA interference invivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle 2008, 7:1870-1879.
12. Bougeard G., Sesboüé R., Baert-Desurmont S., Vasseur S., Martin C., Tinat J., Brugières L., Chompret A., de Paillerets B.B., Stoppa-Lyonnet D., et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J.Med. Genet. 2008, 45:535-538. French LFS working group.
13. Braicu C., Pileczki V., Irimie A., Berindan-Neagoe I. p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells. Mol. Cell. Biochem. 2013, 381:61-68.
14. Brázdová M., Navrátilová L., Tichý V., Němcová K., Lexa M., Hrstka R., Pečinka P., Adámik M., Vojtesek B., Paleček E., et al. Preferential binding of hot spot mutant p53 proteins to supercoiled DNA invitro and in cells. PLoS ONE 2013, 8:e59567.
15. Buganim Y., Kalo E., Brosh R., Besserglick H., Nachmany I., Rais Y., Stambolsky P., Tang X., Milyavsky M., Shats I., et al. Mutant p53 protectscells from 12-O-tetradecanoylphorbol-13-acetate-induced death byattenuating activating transcription factor 3 induction. Cancer Res. 2006, 66:10750-10759.
16. Butler J.S., Loh S.N. Structure, function, and aggregation of thezinc-free form of the p53 DNA binding domain. Biochemistry 2003, 42:2396-2403.
17. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 2002, 8:282-288.
18. Bykov V.J., Issaeva N., Zache N., Shilov A., Hultcrantz M., Bergman J., Selivanova G., Wiman K.G. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J.Biol. Chem. 2005, 280:30384-30391.
19. Capponcelli S., Pedrini E., Cerone M.A., Corti V., Fontanesi S., Alessio M., Bachi A., Soddu S., Ribatti D., Picci P., et al. Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation. Hum. Mutat. 2005, 26:94-103.
20. Chee J.L., Saidin S., Lane D.P., Leong S.M., Noll J.E., Neilsen P.M., Phua Y.T., Gabra H., Lim T.M. Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9. Cell Cycle 2013, 12:278-288.
21. Chicas A., Molina P., Bargonetti J. Mutant p53 forms a complexwith Sp1 on HIV-LTR DNA. Biochem. Biophys. Res. Commun. 2000, 279:383-390.
22. Choudhury S., Kolukula V.K., Preet A., Albanese C., Avantaggiati M.L. Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy?. Cell Cycle 2013, 12:1022-1029.
23. Coffill C.R., Muller P.A., Oh H.K., Neo S.P., Hogue K.A., Cheok C.F., Vousden K.H., Lane D.P., Blackstock W.P., Gunaratne J. Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep. 2012, 13:638-644.
24. Cooks T., Pateras I.S., Tarcic O., Solomon H., Schetter A.J., Wilder S., Lozano G., Pikarsky E., Forshew T., Rosenfeld N., et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013, 23:634-646.
25. Demma M., Maxwell E., Ramos R., Liang L., Li C., Hesk D., Rossman R., Mallams A., Doll R., Liu M., et al. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J.Biol. Chem. 2010, 285:10198-10212.
26. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22.
27. Di Agostino S., Strano S., Emiliozzi V., Zerbini V., Mottolese M., Sacchi A., Blandino G., Piaggio G. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006, 10:191-202.
28. Di Como C.J., Gaiddon C., Prives C. p73 function is inhibited bytumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 1999, 19:1438-1449.
29. Dittmer D., Pati S., Zambetti G., Chu S., Teresky A.K., Moore M., Finlay C., Levine A.J. Gain of function mutations in p53. Nat. Genet. 1993, 4:42-46.
30. Do P.M., Varanasi L., Fan S., Li C., Kubacka I., Newman V., Chauhan K., Daniels S.R., Boccetta M., Garrett M.R., et al. Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev. 2012, 26:830-845.
31. Dong P., Xu Z., Jia N., Li D., Feng Y. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol. Cancer 2009, 8:103.
32. Dong P., Karaayvaz M., Jia N., Kaneuchi M., Hamada J., Watari H., Sudo S., Ju J., Sakuragi N. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2012.
33. Doyle B., Morton J.P., Delaney D.W., Ridgway R.A., Wilkins J.A., Sansom O.J. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J.Pathol. 2010, 222:129-137.
34. Dumay A., Feugeas J.P., Wittmer E., Lehmann-Che J., Bertheau P., Espie M., Plassa L.F., Cottu P., Marty M., Andre F., et al. Distinct tumor protein p53 mutants in breast cancer subgroups. International journal of cancer Journal international du cancer 2013, 132:1227-1231.
35. El-Hizawi S., Lagowski J.P., Kulesz-Martin M., Albor A. Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins. Cancer Res. 2002, 62:3264-3270.
36. Esser C., Scheffner M., Höhfeld J. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J.Biol. Chem. 2005, 280:27443-27448.
37. Fontemaggi G., Dell'Orso S., Trisciuoglio D., Shay T., Melucci E., Fazi F., Terrenato I., Mottolese M., Muti P., Domany E., et al. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat. Struct. Mol. Biol. 2009, 16:1086-1093.
38. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999, 286:2507-2510.
39. Frank A.K., Pietsch E.C., Dumont P., Tao J., Murphy M.E. Wild-type and mutant p53 proteins interact with mitochondrial caspase-3. Cancer Biol. Ther. 2011, 11:740-745.
40. Freed-Pastor W.A., Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012, 26:1268-1286.
41. Freed-Pastor W.A., Mizuno H., Zhao X., Langerød A., Moon S.H., Rodriguez-Barrueco R., Barsotti A., Chicas A., Li W., Polotskaia A., et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148:244-258.
42. Gaiddon C., Lokshin M., Ahn J., Zhang T., Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 2001, 21:1874-1887.
43. Gerwin B.I., Spillare E., Forrester K., Lehman T.A., Kispert J., Welsh J.A., Pfeifer A.M., Lechner J.F., Baker S.J., Vogelstein B., et al. Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc. Natl. Acad. Sci. USA 1992, 89:2759-2763.
44. Girardini J.E., Napoli M., Piazza S., Rustighi A., Marotta C., Radaelli E., Capaci V., Jordan L., Quinlan P., Thompson A., et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011, 20:79-91.
45. Gloushankova N., Ossovskaya V., Vasiliev J., Chumakov P., Kopnin B. Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes. Oncogene 1997, 15:2985-2989.
46. Gogna R., Madan E., Kuppusamy P., Pati U. Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression. J.Biol. Chem. 2012, 287:2907-2914.
47. Göhler T., Jäger S., Warnecke G., Yasuda H., Kim E., Deppert W. Mutant p53 proteins bind DNA in a DNA structure-selective mode. Nucleic Acids Res. 2005, 33:1087-1100.
48. Grugan K.D., Vega M.E., Wong G.S., Diehl J.A., Bass A.J., Wong K.K., Nakagawa H., Rustgi A.K. A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion. Cancer Biol. Ther. 2013, 14:14.
49. Gualberto A., Aldape K., Kozakiewicz K., Tlsty T.D. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc. Natl. Acad. Sci. USA 1998, 95:5166-5171.
50. Gurova K.V., Rokhlin O.W., Budanov A.V., Burdelya L.G., Chumakov P.M., Cohen M.B., Gudkov A.V. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res. 2003, 63:2905-2912.
51. Gurtner A., Starace G., Norelli G., Piaggio G., Sacchi A., Bossi G. Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J.Biol. Chem. 2010, 285:14160-14169.
52. Halevy O., Michalovitz D., Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 1990, 250:113-116.
53. Hanel W., Marchenko N., Xu S., Yu S.X., Weng W., Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ. 2013, 20:898-909.
54. Hsiao M., Low J., Dorn E., Ku D., Pattengale P., Yeargin J., Haas M. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am. J. Pathol. 1994, 145:702-714.
55. Huang X., Zhang Y., Tang Y., Butler N., Kim J., Guessous F., Schiff D., Mandell J., Abounader R. A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy. Neoplasia 2013, 15:952-965.
56. Hui L., Zheng Y., Yan Y., Bargonetti J., Foster D.A. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene 2006, 25:7305-7310.
57. Jackson J.G., Lozano G. The mutant p53 mouse as a pre-clinical model. Oncogene 2013, 32:4325-4330.
58. Jackson E.L., Olive K.P., Tuveson D.A., Bronson R., Crowley D., Brown M., Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005, 65:10280-10288.
59. Jackson J.G., Pant V., Li Q., Chang L.L., Quintás-Cardama A., Garza D., Tavana O., Yang P., Manshouri T., Li Y., et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012, 21:793-806.
60. Jia S., Zhao L., Tang W., Luo Y. The gain of function of p53 mutant p53S in promoting tumorigenesis by cross-talking with H-RasV12. Int. J. Biol. Sci. 2012, 8:596-605.
61. Joerger A.C., Fersht A.R. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 2007, 26:2226-2242.
62. Joerger A.C., Fersht A.R. Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 2008, 77:557-582.
63. Kalo E., Kogan-Sakin I., Solomon H., Bar-Nathan E., Shay M., Shetzer Y., Dekel E., Goldfinger N., Buganim Y., Stambolsky P., et al. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. J.Cell Sci. 2012, 125:5578-5586.
64. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
65. Kawamata H., Omotehara F., Nakashiro K., Uchida D., Shinagawa Y., Tachibana M., Imai Y., Fujimori T. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage. Int. J. Oncol. 2007, 30:1089-1097.
66. Kawamura T., Suzuki J., Wang Y.V., Menendez S., Morera L.B., Raya A., Wahl G.M., Izpisúa Belmonte J.C. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009, 460:1140-1144.
67. King S.I., Purdie C.A., Bray S.E., Quinlan P.R., Jordan L.B., Thompson A.M., Meek D.W. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom. Breast Cancer Res. 2012, 14:R40.
68. Kravchenko J.E., Ilyinskaya G.V., Komarov P.G., Agapova L.S., Kochetkov D.V., Strom E., Frolova E.I., Kovriga I., Gudkov A.V., Feinstein E., Chumakov P.M. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc. Natl. Acad. Sci. USA 2008, 105:6302-6307.
69. Lambert J.M., Gorzov P., Veprintsev D.B., Söderqvist M., Segerbäck D., Bergman J., Fersht A.R., Hainaut P., Wiman K.G., Bykov V.J. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009, 15:376-388.
70. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-872.
71. Lányi A., Deb D., Seymour R.C., Ludes-Meyers J.H., Subler M.A., Deb S. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain. Oncogene 1998, 16:3169-3176.
72. Lee M.K., Teoh W.W., Phang B.H., Tong W.M., Wang Z.Q., Sabapathy K. Cell-type, dose, and mutation-type specificity dictate mutant p53 functions invivo. Cancer Cell 2012, 22:751-764.
73. Lehmann B.D., Pietenpol J.A. Targeting mutant p53 in human tumors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2012, 30:3648-3650.
74. Lehmann S., Bykov V.J., Ali D., Andren O., Cherif H., Tidefelt U., Uggla B., Yachnin J., Juliusson G., Moshfegh A., et al. Targeting p53 invivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol. 2012, 30:3633-3639.
75. Leroy B., Fournier J.L., Ishioka C., Monti P., Inga A., Fronza G., Soussi T. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. 2013, 41(Database issue):D962-D969.
76. Li R., Sutphin P.D., Schwartz D., Matas D., Almog N., Wolkowicz R., Goldfinger N., Pei H., Prokocimer M., Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 1998, 16:3269-3277.
77. Li D., Marchenko N.D., Moll U.M. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ. 2011, 18:1904-1913.
78. Li D., Marchenko N.D., Schulz R., Fischer V., Velasco-Hernandez T., Talos F., Moll U.M. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol. Cancer Res. 2011, 9:577-588.
79. Lim L.Y., Vidnovic N., Ellisen L.W., Leong C.O. Mutant p53 mediates survival of breast cancer cells. Br. J. Cancer 2009, 101:1606-1612.
80. Lin C., Liang Y., Zhu H., Zhang J., Zhong X. R280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3β/PTEN pathway. Neurosci. Lett. 2012, 529:60-65.
81. Liu E.Y., Ryan K.M. Autophagy and cancer-issues we need to digest. J.Cell Sci. 2012, 125:2349-2358.
82. Liu K., Ling S., Lin W.C. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol. Cell. Biol. 2011, 31:4464-4481.
83. Liu X., Wilcken R., Joerger A.C., Chuckowree I.S., Amin J., Spencer J., Fersht A.R. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res. 2013, 41:6034-6044.
84. Loging W.T., Reisman D. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53. Cancer Epidemiol Biomarkers Prev. 1999, 8:1011-1016.
85. Loh S.N. The missing zinc: p53 misfolding and cancer. Metallomics: integrated biometal science 2010, 2:442-449.
86. Lu X., Liu D.P., Xu Y. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis. Oncogene 2013, 32:2900-2906.
87. Lukashchuk N., Vousden K.H. Ubiquitination and degradation of mutant p53. Mol. Cell. Biol. 2007, 27:8284-8295.
88. Madar S., Harel E., Goldstein I., Stein Y., Kogan-Sakin I., Kamer I., Solomon H., Dekel E., Tal P., Goldfinger N., et al. Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta. PLoS ONE 2013, 8:e61353.
89. Marión R.M., Strati K., Li H., Murga M., Blanco R., Ortega S., Fernandez-Capetillo O., Serrano M., Blasco M.A. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009, 460:1149-1153.
90. Maslon M.M., Hupp T.R. Drug discovery and mutant p53. Trends Cell Biol. 2010, 20:542-555.
91. Matas D., Sigal A., Stambolsky P., Milyavsky M., Weisz L., Schwartz D., Goldfinger N., Rotter V. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J. 2001, 20:4163-4172.
92. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
93. Morselli E., Tasdemir E., Maiuri M.C., Galluzzi L., Kepp O., Criollo A., Vicencio J.M., Soussi T., Kroemer G. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 2008, 7:3056-3061.
94. Morton J.P., Timpson P., Karim S.A., Ridgway R.A., Athineos D., Doyle B., Jamieson N.B., Oien K.A., Lowy A.M., Brunton V.G., et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl. Acad. Sci. USA 2010, 107:246-251.
95. Muller P.A., Vousden K.H. p53 mutations in cancer. Nat. Cell Biol. 2013, 15:2-8.
96. Muller P.A., Caswell P.T., Doyle B., Iwanicki M.P., Tan E.H., Karim S., Lukashchuk N., Gillespie D.A., Ludwig R.L., Gosselin P., et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009, 139:1327-1341.
97. Muller P.A., Trinidad A.G., Timpson P., Morton J.P., Zanivan S., van den Berghe P.V., Nixon C., Karim S.A., Caswell P.T., Noll J.E., et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 2012, 32:1252-1265.
98. Murphy K.L., Dennis A.P., Rosen J.M. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2000, 14:2291-2302.
99. Narendran A., Ganjavi H., Morson N., Connor A., Barlow J.W., Keystone E., Malkin D., Freedman M.H. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp. Hematol. 2003, 31:693-701.
100. Neilsen P.M., Noll J.E., Mattiske S., Bracken C.P., Gregory P.A., Schulz R.B., Lim S.P., Kumar R., Suetani R.J., Goodall G.J., Callen D.F. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene 2012, 32:2992-3000.
101. Nguyen C.H., Lang B.J., Chai R.C., Vieusseux J.L., Kouspou M.M., Price J.T. Heat-shock factor 1 both positively and negatively affects cellular clonogenic growth depending on p53 status. Biochem. J. 2013, 452:321-329.
102. Noll J.E., Jeffery J., Al-Ejeh F., Kumar R., Khanna K.K., Callen D.F., Neilsen P.M. Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11. Oncogene 2012, 31:2836-2848.
103. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860.
104. Ostman A., Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr. Opin. Genet. Dev. 2009, 19:67-73.
105. Patocs A., Zhang L., Xu Y., Weber F., Caldes T., Mutter G.L., Platzer P., Eng C. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N.Engl. J. Med. 2007, 357:2543-2551.
106. Petitjean A., Achatz M.I., Borresen-Dale A.L., Hainaut P., Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007, 26:2157-2165.
107. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 2010, 316:1324-1331.
108. Pintus S.S., Ivanisenko N.V., Demenkov P.S., Ivanisenko T.V., Ramachandran S., Kolchanov N.A., Ivanisenko V.A. The substitutions G245C and G245D in the Zn(2+)-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain. J.Biomol. Struct. Dyn. 2013, 31:78-86.
109. Pohl U., Wagenknecht B., Naumann U., Weller M. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 1999, 9:29-37.
110. Preuss U., Kreutzfeld R., Scheidtmann K.H. Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation. Int. J. Cancer 2000, 88:162-171.
111. Puca R., Nardinocchi L., Bossi G., Sacchi A., Rechavi G., Givol D., D'Orazi G. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. Exp. Cell Res. 2009, 315:67-75.
112. Puca R., Nardinocchi L., Porru M., Simon A.J., Rechavi G., Leonetti C., Givol D., D'Orazi G. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 2011, 10:1679-1689.
113. Pugacheva E.N., Ivanov A.V., Kravchenko J.E., Kopnin B.P., Levine A.J., Chumakov P.M. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 2002, 21:4595-4600.
114. Quante T., Otto B., Brázdová M., Kejnovská I., Deppert W., Tolstonog G.V. Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity. Cell Cycle 2012, 11:3290-3303.
115. Restle A., Färber M., Baumann C., Böhringer M., Scheidtmann K.H., Müller-Tidow C., Wiesmüller L. Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants. Nucleic Acids Res. 2008, 36:5362-5375.
116. Rieber M., Strasberg-Rieber M. Hypoxia, Mn-SOD and H(2)O(2) regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells. Biochem. Pharmacol. 2012, 84:1563-1570.
117. Rodriguez O.C., Choudhury S., Kolukula V., Vietsch E.E., Catania J., Preet A., Reynoso K., Bargonetti J., Wellstein A., Albanese C., Avantaggiati M.L. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle 2012, 11:4436-4446.
118. Roger L., Jullien L., Gire V., Roux P. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J.Cell Sci. 2010, 123:1295-1305.
119. Sarig R., Rivlin N., Brosh R., Bornstein C., Kamer I., Ezra O., Molchadsky A., Goldfinger N., Brenner O., Rotter V. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J.Exp. Med. 2010, 207:2127-2140.
120. Sauer L., Gitenay D., Vo C., Baron V.T. Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene 2010, 29:2628-2637.
121. Schilling T., Kairat A., Melino G., Krammer P.H., Stremmel W., Oren M., Müller M. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2010, 394:817-823.
122. Scian M.J., Stagliano K.E., Deb D., Ellis M.A., Carchman E.H., Das A., Valerie K., Deb S.P., Deb S. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 2004, 23:4430-4443.
123. Scian M.J., Stagliano K.E., Ellis M.A., Hassan S., Bowman M., Miles M.F., Deb S.P., Deb S. Modulation of gene expression by tumor-derived p53 mutants. Cancer Res. 2004, 64:7447-7454.
124. Shi X.B., Nesslinger N.J., Deitch A.D., Gumerlock P.H., deVere White R.W. Complex functions of mutant p53 alleles from human prostate cancer. Prostate 2002, 51:59-72.
125. Singh S., Singh P.P. Statin a day keeps cancer at bay. World journal of clinical oncology 2013, 4:43-46.
126. Smith P.D., Crossland S., Parker G., Osin P., Brooks L., Waller J., Philp E., Crompton M.R., Gusterson B.A., Allday M.J., Crook T. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene 1999, 18:2451-2459.
127. Solomon H., Buganim Y., Kogan-Sakin I., Pomeraniec L., Assia Y., Madar S., Goldstein I., Brosh R., Kalo E., Beatus T., et al. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. J.Cell Sci. 2012, 125:3144-3152.
128. Sonego M., Schiappacassi M., Lovisa S., Dall'Acqua A., Bagnoli M., Lovat F., Libra M., D'Andrea S., Canzonieri V., Militello L., et al. Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO molecular medicine 2013, 5:707-722.
129. Song H., Hollstein M., Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat. Cell Biol. 2007, 9:573-580.
130. Stambolsky P., Tabach Y., Fontemaggi G., Weisz L., Maor-Aloni R., Siegfried Z., Shiff I., Kogan I., Shay M., Kalo E., et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010, 17:273-285.
131. Strano S., Fontemaggi G., Costanzo A., Rizzo M.G., Monti O., Baccarini A., Del Sal G., Levrero M., Sacchi A., Oren M., Blandino G. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J.Biol. Chem. 2002, 277:18817-18826.
132. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat. Rev. Drug Discov. 2010, 9:643-660.
133. Su X., Chakravarti D., Cho M.S., Liu L., Gi Y.J., Lin Y.L., Leung M.L., El-Naggar A.K., Creighton C.J., Suraokar M.B., et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010, 467:986-990.
134. Suh Y.A., Post S.M., Elizondo-Fraire A.C., Maccio D.R., Jackson J.G., El-Naggar A.K., Van Pelt C., Terzian T., Lozano G. Multiple stress signals activate mutant p53 invivo. Cancer Res. 2011, 71:7168-7175.
135. Sun Y., Nakamura K., Wendel E., Colburn N. Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. USA 1993, 90:2827-2831.
136. Tan E.H., Morton J.P., Timpson P., Tucci P., Melino G., Flores E.R., Sansom O.J., Vousden K.H., Muller P.A. Functions of TAp63 and p53 in restraining the development of metastatic cancer. Oncogene 2013.
137. Tasdemir E., Maiuri M.C., Galluzzi L., Vitale I., Djavaheri-Mergny M., D'Amelio M., Criollo A., Morselli E., Zhu C., Harper F., et al. Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol. 2008, 10:676-687.
138. Trepel M., Groscurth P., Malipiero U., Gulbins E., Dichgans J., Weller M. Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. J.Neurooncol. 1998, 39:19-32.
139. Trinidad A.G., Muller P.A., Cuellar J., Klejnot M., Nobis M., Valpuesta J.M., Vousden K.H. Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity. Mol. Cell 2013, 50:805-817.
140. Tsang W.P., Ho F.Y., Fung K.P., Kong S.K., Kwok T.T. p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. International journal of cancer Journal international du cancer 2005, 114:331-336.
141. Tucci P., Agostini M., Grespi F., Markert E.K., Terrinoni A., Vousden K.H., Muller P.A.J., Dötsch V., Kehrloesser S., Sayan B.S., et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc. Natl. Acad. Sci. USA 2012, 109:15312-15317.
142. Vakifahmetoglu-Norberg H., Kim M., Xia H.G., Iwanicki M.P., Ofengeim D., Coloff J.L., Pan L., Ince T.A., Kroemer G., Brugge J.S., Yuan J. Chaperone-mediated autophagy degrades mutant p53. Genes Dev. 2013, 27:1718-1730.
143. Vaughan C.A., Frum R., Pearsall I., Singh S., Windle B., Yeudall A., Deb S.P., Deb S. Allele specific gain-of-function activity of p53 mutants in lung cancer cells. Biochem. Biophys. Res. Commun. 2012, 428:6-10.
144. Vaughan C.A., Singh S., Windle B., Sankala H.M., Graves P.R., Andrew Yeudall W., Deb S.P., Deb S. p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity. Arch. Biochem. Biophys. 2012, 518:79-88.
145. Verhaegh G.W., Parat M.O., Richard M.J., Hainaut P. Modulation of p53 protein conformation and DNA-binding activity by intracellular chelation of zinc. Mol. Carcinog. 1998, 21:205-214.
146. Vikhanskaya F., Lee M.K., Mazzoletti M., Broggini M., Sabapathy K. Cancer-derived p53 mutants suppress p53-target gene expression-potential mechanism for gain of function of mutant p53. Nucleic Acids Res. 2007, 35:2093-2104.
147. Walerych D., Napoli M., Collavin L., Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012, 33:2007-2017.
148. Wang X., Simon R. Identification of potential synthetic lethal genes to p53 using a computational biology approach. BMC Med. Genomics 2013, 6:30.
149. Wang Y., Suh Y.A., Fuller M.Y., Jackson J.G., Xiong S., Terzian T., Quintás-Cardama A., Bankson J.A., El-Naggar A.K., Lozano G. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J.Clin. Invest. 2011, 121:893-904.
150. Wang W., Cheng B., Miao L., Mei Y., Wu M. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression. Cell Death Dis. 2013, 4:e574.
151. Wang X., Chen J.X., Liu J.P., You C., Liu Y.H., Mao Q. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide. Ann. Surg. Oncol. 2013, Published online November 19, 2013. 10.1245/s10434-013-3380-0.
152. Weisz L., Zalcenstein A., Stambolsky P., Cohen Y., Goldfinger N., Oren M., Rotter V. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res. 2004, 64:8318-8327.
153. Weisz L., Oren M., Rotter V. Transcription regulation by mutant p53. Oncogene 2007, 26:2202-2211.
154. Wiman K.G. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 2010, 29:4245-4252.
155. Wong R.P., Tsang W.P., Chau P.Y., Co N.N., Tsang T.Y., Kwok T.T. p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol. Cancer Ther. 2007, 6:1054-1061.
156. Xie T.X., Zhou G., Zhao M., Sano D., Jasser S.A., Brennan R.G., Myers J.N. Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells. Laryngoscope 2013, 123:1416-1423.
157. Yan W., Chen X. Identification of GRO1 as a critical determinant for mutant p53 gain of function. J.Biol. Chem. 2009, 284:12178-12187.
158. Yan W., Chen X. Characterization of functional domains necessary for mutant p53 gain of function. J.Biol. Chem. 2010, 285:14229-14238.
159. Yan W., Liu G., Scoumanne A., Chen X. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations. Cancer Res. 2008, 68:6789-6796.
160. Yan W., Liu S., Xu E., Zhang J., Zhang Y., Chen X., Chen X. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene 2013, 32:599-609.
161. Yeudall W.A., Vaughan C.A., Miyazaki H., Ramamoorthy M., Choi M.Y., Chapman C.G., Wang H., Black E., Bulysheva A.A., Deb S.P., et al. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 2012, 33:442-451.
162. Yi L., Lu C., Hu W., Sun Y., Levine A.J. Multiple roles of p53-related pathways in somatic cell reprogramming and stem cell differentiation. Cancer Res. 2012, 72:5635-5645.
163. Yi Y.W., Kang H.J., Kim H.J., Kong Y., Brown M.L., Bae I. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget 2013, 4:984-994.
164. Yoshikawa K., Hamada J., Tada M., Kameyama T., Nakagawa K., Suzuki Y., Ikawa M., Hassan N.M., Kitagawa Y., Moriuchi T. Mutant p53 R248Q but not R248W enhances invitro invasiveness of human lung cancer NCI-H1299 cells. Biomed. Res. 2010, 31:401-411.
165. Yu X., Vazquez A., Levine A.J., Carpizo D.R. Allele-specific p53 mutant reactivation. Cancer Cell 2012, 21:614-625.
166. Zache N., Lambert J.M., Rökaeus N., Shen J., Hainaut P., Bergman J., Wiman K.G., Bykov V.J. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol. Oncol. 2008, 2:70-80.
167. Zalcenstein A., Stambolsky P., Weisz L., Müller M., Wallach D., Goncharov T.M., Krammer P.H., Rotter V., Oren M. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 2003, 22:5667-5676.
168. Zalcenstein A., Weisz L., Stambolsky P., Bar J., Rotter V., Oren M. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene 2006, 25:359-369.
169. Zerdoumi Y., Aury-Landas J., Bonaïti-Pellié C., Derambure C., Sesboüé R., Renaux-Petel M., Frebourg T., Bougeard G., Flaman J.M. Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients. Hum. Mutat. 2013, 34:453-461.
170. Zhang Y., Yan W., Chen X. Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions. J.Biol. Chem. 2011, 286:16218-16228.
171. Zhu H., Mao Q., Lin Y., Yang K., Xie L. RNA interference targeting mutant p53 inhibits growth and induces apoptosis in DU145 human prostate cancer cells. Med. Oncol. 2011, 28(Suppl 1):S381-S387.
172. Zhu H.B., Yang K., Xie Y.Q., Lin Y.W., Mao Q.Q., Xie L.P. Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World J. Surg. Oncol. 2013, 11:22.